anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method for making a flexible film having pressure sensitive adhesive protected from inadvertent adherence. The method coats a forming screen with an interconnected layer of pressure sensitive adhesive and places a piece of flexible film in contact with the layer of adhesive. The layer of adhesive preferentially adheres to the piece of flexible film. The forming screen has a plurality of recesses therein. The coating step applies the layer of adhesive without bridging the recesses. Another step forms the piece of flexible film to create a plurality of protrusions extending into the recesses. The plurality of protrusions are registered with the interconnected layer of pressure sensitive adhesive by virtue of using the same screen to transfer adhesive and to form protrusions. The forming screen may be wrapped around a rotating drum and the piece of flexible film may be a portion of a continuous web of flexible film. Preferably, the plurality of protrusions are conical, with a base diameter of 0.015 inches to 0.030 inches, a center-to-center spacing of 0.03 to 0.06 inches, and a protrusion height of 0.004 to 0.012 inches.
Myovolt delivers vibration with a frequency between 50-80 Hz. Myovolt intensity will be set to \~up to 2X the participant's initial Myovolt perception threshold. If the stimulation does not feel strong, the participant will be asked to manually increase the intensity until it feels strong but comfortable.
Our overarching hypothesis is that the consequences of surgical sepsis (death and poor quality of life) are the result of an unresolving host leukocyte dyscrasia, similar to other chronic conditions such as cancer and autoimmune disease. Specifically, the preferential expansion and self-perpetuation of myeloid-derived suppressor cells (MDSCs), propagated in part through epigenetic changes in both bone marrow (BM) progenitors and MDSCs, drives non-acute infectious and noninfectious complications after sepsis.

This Program will investigate in human surgical sepsis the underlying mechanisms that drive 'dysfunctional myelopoiesis', expansion of MDSC populations, suppressed T-cell quantities/function, and the development of patient's immunosuppressive/inflammatory endotypes. We will primarily focus on how MDSC expansion evolves over time in an observational study that follows surgical sepsis patients who do or do not rapidly recover. There are three specific aims: Aim 1. To test the hypothesis that perpetuation of host MDSCs after acute surgical sepsis drives poor long-term clinical outcomes in surgical sepsis, including but not limited to increased secondary infections. Aim 2. To test the hypothesis that failure to recover from surgical sepsis is driven by modifiable epigenetic alterations in circulating MDSCs that induce and prolong immunosuppressive endotypes. Aim 3. To identify the distinct immunosuppressive mechanisms of MDSCs from surgical sepsis patients over time, including immunometabolism, check-point inhibition, reactive oxygen and nitrogen production, and substrate availability. Using the established clinical infrastructure of the Sepsis and Critical Illness Research Center (SCIRC), a team science approach will be employed with collaborating PI's coming from multiple clinical and basic science disciplines. Aim 4. To test the hypothesis that in response to an initial inflammatory stimulus (severe blunt trauma) associated with a high risk of in-hospital sepsis, bone marrow (BM) hematopoietic stem cells (HSCs) promote immunosuppressive myelopoiesis at the expense of lymphopoiesis. With subsequent sepsis development, MDSCs induce their continued expansion through exocrine and paracrine signaling to HSCs. HSCs and MDSCs derived from severe blunt trauma patients will be analyzed for epigenetic and functional changes that initiate sepsis and continue the expansion of immunosuppressive MDSCs.
The Treatment arm has alerting enabled in their device during the 6-month randomization period. Treatment arm patients also have alerting enabled in the post-randomization period. Once a patient arrives at the ER, the standard of care triage process for MI is followed and that is outside of the ALERTS Study protocol. With Amendment the Treatment arm was re-defined as an ALARMS_ON group which included A) Control patients after the randomization period and until database lock (4/1/2014); and, b) Treatment patients both during the randomization period and after the randomization period until database lock (4/1/2014).
It is well established that Alzheimer's disease (AD) is associated with insulin resistance and, hence, abnormal glucose metabolism. In fact, abnormalities in the brain's uptake of glucose can be observed on PET imaging in advance of clinical symptoms. In patients with established dementia due to AD, the severity of cognitive impairment is strongly correlated with the decrease in glucose uptake. Ketone bodies, the products of fat metabolism, can serve as a "backup" fuel when glucose is unavailable. Ketone body metabolism appears to bypass the metabolic processes that are abnormal in AD and may provide better nourishment for neurons. As a result, ketone body metabolism may slow cognitive decline or even improve cognition in patients with AD.

Participants will be 60 people, age 60 or older, with MCI or mild probable AD and without significant cardiovascular disease. They will be required to obtain the consent of their primary care physicians for their participation. Each patient will have a study partner who is cognitively healthy, lives with the participant, and can help him/her adhere to the diet. A research dietitian will teach participants and partners the new diet and monitor participants' adherence with food logs, in-person assessments, and urine ketone testing. After an initial baseline visit, participants will complete four in-person assessments during which adherence to the diet will be assessed and neurocognitive tests will be administered. It is hypothesized that the MAD will be feasible and well tolerated by seniors with MCI and AD. It is further hypothesized that adherence to the MAD will be associated with a greater increase (or less decline) in cognitive test scores than the placebo diet, particularly for those participants who do not carry an ApoE ε4 allele.
In Stage 3, PTC299 will be given BID or TID (for total of 42 \[for BID\] or 63 \[for TID\] doses) orally about same time per day starting on Day 1 in each 3-week (21-day) cycle. Starting dose will be 1 dose level below maximum tolerated dose (MTD) from Stage 2 or 80 mg/dose BID if 100 mg/dose TID in Stage 2 exceeds MTD. Dose escalation will be based on safety evaluations by Sponsor's medical monitor in Cycle 1. Treatment cycles can continue if therapy appears to be safely offering tumor control to participant. Participants will also receive docetaxel as a 1-hour IV infusion on Day 1 per cycle at starting dose of 75 mg/m\^2 with body surface area calculation based on body weight. Dose will be sequentially reduced to 60 and 50 mg/m\^2 in participants with a docetaxel-related dose-limiting toxicity (DLT). Participants will be medicated with oral corticosteroids with docetaxel administration. Recommended dose is 8 mg BID dexamethasone for 3 days starting 1 day prior to docetaxel administration.
Death and disability from iron related damage to the heart remain the most serious issue facing transfusion-dependent patients with thalassemia. However, over the past decade there have been several reports of improved survival and fewer cardiac complications. This improvement may be related to the availability of three chelators and also the accurate measurement of iron stores in various organs (e.g. heart and liver) with magnetic resonance imaging, which allows for personalized, tailored medical care for patients. The chelator characteristics, side effect profiles, and ability to remove iron from specific organs differ among the chelators, suggesting that combination therapy may be beneficial. Using two drugs at lower doses may be more tolerable than escalating doses of a single drug and may improve iron removal. The combination of deferoxamine and deferiprone has been shown to be particularly beneficial for reducing cardiac iron, but it requires a painful injection/infusion, which hinders adherence. This pilot study aims to investigate the safety of an oral-only combination chelator regimen (deferasirox and deferiprone) in individuals with thalassemia major with poorly controlled iron overload and to assess how well this chelator combination lowers iron stores over one year.
BACKGROUND: Cancer-associated fibroblasts (CAFs), mainly responsible for the desmoplastic reaction hallmark of intrahepatic Cholangiocarcinoma (iCCA), likely have a role in tumor aggressiveness and resistance to therapy, although the molecular mechanisms involved are unknown. Aim of the study is to investigate how targeting hCAF/iCCA cross-talk with a Notch1 inhibitor, namely Crenigacestat, may affect cancer progression.
METHODS: We used different in vitro models in 2D and established new 3D hetero-spheroids with iCCA cells and human (h)CAFs. The results were confirmed in a xenograft model, and explanted tumoral tissues underwent transcriptomic and bioinformatic analysis.
RESULTS: hCAFs/iCCA cross-talk sustains increased migration of both KKU-M213 and KKU-M156 cells, while Crenigacestat significantly inhibits only the cross-talk stimulated migration. Hetero-spheroids grew larger than homo-spheroids, formed by only iCCA cells. Crenigacestat significantly reduced the invasion and growth of hetero- but not of homo-spheroids. In xenograft models, hCAFs/KKU-M213 tumors grew significantly larger than KKU-M213 tumors, but were significantly reduced in volume by Crenigacestat treatment, which also significantly decreased the fibrotic reaction. Ingenuity pathway analysis revealed that genes of hCAFs/KKU-M213 but not of KKU-M213 tumors increased tumor lesions, and that Crenigacestat treatment inhibited the modulated canonical pathways. Cell cycle checkpoints were the most notably modulated pathway and Crenigacestat reduced CCNE2 gene expression, consequently inducing cell cycle arrest. In hetero-spheroids, the number of cells increased in the G2/M cell cycle phase, while Crenigacestat significantly decreased cell numbers in the G2/M phase in hetero but not in homo-spheroids.
CONCLUSIONS: The hCAFs/iCCA cross-talk is a new target for reducing cancer progression with drugs such as Crenigacestat.
Participants assigned to Attention Skills Training will receive 6-weeks of self-directed, online skills training on attention regulation skills for coping with distress. Six weekly modules will include 10-15 minutes of narrated videos, as well as suggestions for activities and skills practices between modules. Participants will also schedule weekly, 5-10 minute calls with an assigned skills training coach to discuss the participant's experience with the skills training.
The invention relates to the field of medicine, in particular to orthopedics and orthodontic departments, and can be used for planning occlusion correction. General and dental history were collected. A mental state is determined. The musculoskeletal system of a patient is analyzed. A polysomnography examination is performed. Body weight and physical size were measured. And performing functional diagnosis. All resulting data are transferred to the calculation unit. When deviations from normal values of the respiratory organs and musculoskeletal systems accompanied by occlusion problems are detected, pathologies affecting organ functions of the human body system in the awake state and/or during sleep and associated with occlusion are diagnosed. Together with the bite correction, an action plan is defined that corrects the identified pathology. The method can reduce functional problems in vivo through sophisticated human diagnostic and therapeutic approaches.
A common perilla granular beverage relieving exterior syndrome and dispelling coldness and a preparing method thereof are disclosed. The beverage is prepared from 40-50 parts by weight of common perilla, 15-25 parts by weight of atalantia buxifolia (poir.) oliv., 10-15 parts by weight of Chinese mosla, 10-15 parts by weight of globe amaranth, 6-10 parts by weight of jasmine flower, 6-10 parts by weight of Illicium difengpi, 6-10 parts by weight of buffalo horn, 6-10 parts by weight of peach tree branches, 6-10 parts by weight of rhino horn, 6-10 parts by weight of hypericum sampsonii, 3-5 parts by weight of xylitol, 3-5 parts by weight of white granulated sugar, 3-5 parts by weight of rock candy and 3-5 parts by weight of citric acid. The method mainly includes steps of 1) pretreating the raw materials, 2) extracting, 3) filtering, 4) concentrating and drying, 5) crushing, 6) mixing, and 7) drying and granulating. Long-term drinking of the beverage has functions of relieving exterior syndrome, dispelling coldness, promoting circulation of qi and normalizing the function of the stomach. The beverage has advantages of delicious taste, rich nutrition and capability of being green and healthy.
Processes for the surface culture of eukaryotic and procaryotic cells on solid carriers. The growth cells are cultured on or in the presence of a solid carrier coated with surface active molecules which act as a major carbon- and energy source. The surface active molecules which have very low solubility in an aqueous solution, are hold in position at the solid surface by hydrophobic forces. The process can be considered as an immobilization of the surface active molecules. The surface active molecules include phospholipids, triglycerides, fatty acids, proteins, synthetic peptides and sterol. The aqueous medium can be any convenient medium without foetal calf serum or albumin-compounds or with reduced amounts of these. The invention also includes products for healing skin leasions.
The present invention relates to a medicine for treating an insufficient syndrome of kidney yang and a preparation method thereof. The medicine is a Chinese patent medicine for treating the insufficient syndrome of kidney yang, which is prepared by taking Chinese medicines as raw materials. At present, the domestic treatment and the abroad treatment mainly relieve symptoms with medicines, the therapeutic effect is not ideal, and the disease is easy to relapse. The medicine is a medicinal preparation prepared from the following raw materials in the proportion by weight: epimedium, prepared rhizome of rehmannia, eucommia bark, atractylodes rhizome and red sage root. Extraction is carried out to the raw materials according to different characteristics of the Chinese medicines, and the raw materials are proportionally mixed and prepared into various corresponding medicinal preparations, such as tablets, capsules, granules, oral liquid, soft extracts, medicinal wine, injections, etc. The prescription and the preparation method are unique, and the therapeutic effect is obvious. The medicine is used for treating the insufficient syndrome of kidney yang, such as sore painful knees and loins, cold limbs, dizziness, lassitude, etc.
The invention provides a nitroreductase, obtainable from a bacterium having the following characteristics as exemplified by examples isolated from $i(Escherichia coli B) and $i(Bacillus amyloliquifaciens): 1) it is flavoprotein having a molecular weight in therange 20-60 Kilodaltons; 2) it requires either NADH or NAD(P)H or analogues thereof as a cofactor; 3) it has a Km for NADH or NAD(P)H in the range 1-100 $g(m)M; and 4) it is capable of reducing either or both nitro groups of CB 1954 and analogues thereof to a cytotoxic form e.g. the hydroxylamine. The sequence of one such nitroreductase is shown in Seq. ID No. 1. The nitroreductase may be conjugated to a tumour targeting agent such as a monoclonal antibody and used to convert prodrugs into active antitumour agents. Such prodrugs and drugs are also provided.
PURPOSE: To obtain the subject composition comprising a linear polysiloxane- polyoxyalkylene block copolymer, a water-soluble alcohol and a specific insoluble conditioning agent in an aqueous medium. CONSTITUTION: This cosmetic composition comprises a linear polysiloxane- polyoxyalkylene block copolymer, a water-soluble alcohol and an insoluble conditioning agent selected from a nonvolatile silicone, a fluorinated oil or wax as a conditioning agent in an aqueous medium. The composition can be used for maintaining and setting a hair style or for treating, protecting and cleaning hair, skin or other keratin components. A copolymer of formula I, formula II, etc., is preferable as the linear block copolymer. Ethanol, ethylene glycol, diethylene glycol, etc., are preferable as the water-soluble alcohol. A silicone oil or silicone rubber is preferable as the nonvolatile insoluble silicone.
Neuropathic pain state is usually refractory to most analgesic regimens and requires polypharmacy for symptomatic relief. Current treatment options for neuropathic pain include both oral and topical medications. Most commonly prescribed oral treatments include antidepressants (eg, amitriptyline, desipramine, and duloxetine), antiepileptics (eg, gabapentin, pregabalin), and opiates such as tramadol and morphine. Current topical treatments include the lidocaine patch and the capsaicin patch. Many patients have inadequate pain relief in spite of these treatment options.

Currently, there are no treatments available for treatment of neuropathy itself other than treating the underlying cause and addressing the symptomatic relief for pain. Current drug therapies for neuropathic pain provide inadequate pain relief and undesirable side effects including sedation and cognitive dysfunction. It is not uncommon to use a combination of agents for the treatment of neuropathic pain to minimize the side effects. Although treating the mild to moderate pain may be relatively easy, it is very challenging for severe neuropathic pain. Although the use of opiates for neuropathic pain is well accepted, it remains controversial because of the potential for abuse and diversion.
OBJECTIVE: The purpose of this study was to determine if an association between Social Vulnerability Index (SVI) and risk-adjusted complications exists in a broad spectrum of surgical patients.
SUMMARY BACKGROUND DATA: Growing evidence supports the impact of social circumstances on surgical outcomes. SVI is a neighborhood-based measure accounting for sociodemographic factors putting communities at risk.
METHODS: This was a multi-hospital, retrospective cohort study including a sample of patients within one healthcare system (2012-2017). Patient addresses were geocoded to determine census tract of residence and estimate SVI. Patients were grouped into low SVI (score<75) and high SVI (score≥75) cohorts. Perioperative variables and postoperative outcomes were tracked and compared using local ACS-NSQIP data. Multivariable logistic regression was performed to generate risk-adjusted odds ratios of postoperative complications in the high SVI cohort.
RESULTS: Overall, 31,224 patients from five hospitals were included. Patients with high SVI were more likely to be racial minorities, have 12/18 medical comorbidities, have high ASA class, be functionally dependent, be treated at academic hospitals, and undergo emergency operations (all p ​< ​0.05). Patients with high SVI had significantly higher rates of 30-day mortality, overall morbidity, respiratory, cardiac and infectious complications, urinary tract infections, postoperative bleeding, non-home discharge, and unplanned readmissions (all p ​< ​0.05). After risk-adjustment, only the associations between high SVI and mortality and unplanned readmission became non-significant.
CONCLUSIONS: High SVI was associated with multiple adverse outcomes even after risk adjustment for preoperative clinical factors. Targeted preventative interventions to mitigate risk of these specific complications should be considered in this high-risk population.
The compsn. contains in aq. soln. (1) at least one surfactant selected from polyethoxylated esters of 12-18C fatty acids and glycerol, the esters having an HLB of 15-18; at least one preservative selected from sodium ethylmercuri-thiosalicylate, a chlorhexidine salt, a phenylmercury salt, a mixture of 30% sodium benzoate and 70% monochloroacetamide, and a dimethyl benzyl alkyl ammonium chloride in which alkyl is 12-18C or mixed alkyl radicals pref. 12-14C and 14-16C radicals and (3) a phosphate buffer, the compsn. having a pH of 6.5-7.5. The compsns. do not sting or irritate and have excellent storage stability using another class of surfactant to that of the principal patent.
Participants with diagnosed lumbar DDD are planned to be managed via intradiscal injection of 0.5-1 ml autologous PRP, whereas participants with FJS will be injected with 0.5 ml of respective solution. All procedures will be performed in surgical theatre under constant fluoroscopic guidance.
AIMS: Physical exercise (PE) can accelerate post-stroke recovery. This study investigated contributions of circRNAs to PE-induced improvements in post-stroke neurological function.
METHODS: Rats subjected to transient middle cerebral artery occlusion were left sedentary or provided running-wheel access for 4 weeks during recovery. CircRNAs from peri-infarct cortex were identified by high-throughput sequencing, and interactions with miRNAs by immunoprecipitation, fluorescence in suit hybridization, and dual-luciferase reporter assays. In vivo circRNA knockdown was achieved using shRNA-AAVs and in vitro overexpression by plasmid transfection. Transmission electron microscopy, western blotting, and TUNEL assays were conducted to explore circRNA contributions to endoplasmic reticulum (ER) stress and neuronal apoptosis. CircRNA levels were measured in plasma from stroke patients by qRT-PCR and associations with neurological scores assessed by Pearson's correlation analysis.
RESULTS: PE upregulated circAnks1b, reduced infarct volume, and mitigated neurological dysfunction, while circAnks1b knockdown exacerbated neurological dysfunction and increased infarct size despite PE. CircAnks1b sponged miR-130b-5p, thereby disinhibiting Pak2 expression. Conversely, Pak2 downregulation disrupted PE-mediated protective ER stress, leading to reduced IRE1/XBP1 and heightened apoptosis. Plasma circAnks1b was higher in stroke patients receiving PE than sedentary patients and correlated negatively with neurological scores.
CONCLUSIONS: CircAnks1b upregulation may be an effective therapeutic strategy for post-stroke recovery.
Patients randomized in the follow up group neither received 131I nor rhTSH. Patients will undergo the same followup procedures as patients randomized to the ablation group, except that at 10 months after randomization, Tg will be measured under LT4 treatment and not after rhTSH stimulation.
This group will be treated with intratissue percutaneous electrolysis using a needle G32 with galvanic current as a cathodic flow electrode in the posterior nerve root of L3, L4 and L5, bilaterally (one times per week / 3 weeks). The intervention will be guided by ultrasound equipment medically certified (Directive 93/42 / EEC) device (EPI Advanced Medicine, Barcelona, Spain).